TRADES
Latest Trades
4121
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 20 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 5,527 0.0084
ARKG 19 Apr 2023 Buy SLGC SOMALOGIC INC 333,347 0.0508
ARKG 19 Apr 2023 Sell EXAS EXACT SCIENCES CORP 11,553 0.0389
ARKG 19 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 157,863 0.0104
ARKG 19 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 11,048 0.0174
ARKG 18 Apr 2023 Buy SLGC SOMALOGIC INC 396,872 0.0611
ARKG 18 Apr 2023 Sell EXAS EXACT SCIENCES CORP 11,308 0.0380
ARKG 18 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 120,357 0.0076
ARKG 18 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 9,514 0.0150
ARKG 17 Apr 2023 Buy SLGC SOMALOGIC INC 70,972 0.0112
ARKG 17 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 150,177 0.0098
ARKG 14 Apr 2023 Buy SLGC SOMALOGIC INC 76,360 0.0118
ARKG 14 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 213,511 0.0140
ARKG 14 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 1,873 0.0030
ARKG 13 Apr 2023 Sell TXG 10X GENOMICS INC 8,280 0.0239
ARKG 13 Apr 2023 Buy SLGC SOMALOGIC INC 56,816 0.0092
ARKG 13 Apr 2023 Sell EXAS EXACT SCIENCES CORP 4,653 0.0164
ARKG 13 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 56,820 0.0039
ARKG 12 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 24,019 0.0170
ARKG 12 Apr 2023 Sell TXG 10X GENOMICS INC 417 0.0012
ARKG 12 Apr 2023 Buy TDOC TELADOC INC 14,208 0.0188
ARKG 12 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 5,144 0.0024
ARKG 12 Apr 2023 Sell EXAS EXACT SCIENCES CORP 342 0.0012
ARKG 12 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 331,951 0.0221
ARKG 12 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 13,764 0.0318
ARKG 12 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 4,042 0.0062
ARKG 11 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 6,576 0.0047
ARKG 11 Apr 2023 Sell TXG 10X GENOMICS INC 2,124 0.0059
ARKG 11 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 699 0.0003
ARKG 11 Apr 2023 Sell EXAS EXACT SCIENCES CORP 8,669 0.0303
ARKG 11 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 979 0.0023
ARKG 10 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 10,088 0.0071
ARKG 10 Apr 2023 Sell TXG 10X GENOMICS INC 7,631 0.0208
ARKG 10 Apr 2023 Buy TDOC TELADOC INC 2,108 0.0028
ARKG 10 Apr 2023 Buy SLGC SOMALOGIC INC 19,335 0.0027
ARKG 10 Apr 2023 Buy PRME PRIME MEDICINE INC 386 0.0002
ARKG 10 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 4,276 0.0078
ARKG 10 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 4,486 0.0020
ARKG 10 Apr 2023 Sell EXAS EXACT SCIENCES CORP 1,237 0.0043
ARKG 10 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 548 0.0000
ARKG 10 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 7,785 0.0182
ARKG 10 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 96 0.0001
ARKG 6 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 13,255 0.0095
ARKG 6 Apr 2023 Sell TXG 10X GENOMICS INC 23,774 0.0655
ARKG 6 Apr 2023 Buy SLGC SOMALOGIC INC 87,204 0.0123
ARKG 6 Apr 2023 Buy PRME PRIME MEDICINE INC 481 0.0003
ARKG 6 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 13,581 0.0257
ARKG 6 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 599 0.0003
ARKG 6 Apr 2023 Sell EXAS EXACT SCIENCES CORP 30,548 0.1052
ARKG 6 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 252 0.0004
ARKG 5 Apr 2023 Buy VERV VERVE THERAPEUTICS INC 5,260 0.0036
ARKG 5 Apr 2023 Sell TXG 10X GENOMICS INC 4,082 0.0109
ARKG 5 Apr 2023 Buy SLGC SOMALOGIC INC 266,081 0.0362
ARKG 5 Apr 2023 Buy PRME PRIME MEDICINE INC 83,508 0.0487
ARKG 5 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 7,357 0.0133
ARKG 5 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 18,124 0.0081
ARKG 5 Apr 2023 Sell INCY INCYTE CORP 26,729 0.1011
ARKG 5 Apr 2023 Sell EXAS EXACT SCIENCES CORP 44,773 0.1482
ARKG 5 Apr 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 9,314 0.0006
ARKG 5 Apr 2023 Buy CRSP CRISPR THERAPEUTICS AG 1,568 0.0035
ARKG 5 Apr 2023 Buy BFLY BUTTERFLY NETWORK INC 1,130,630 0.1260
ARKG 5 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 1,008 0.0015
ARKG 4 Apr 2023 Buy SLGC SOMALOGIC INC 24,226 0.0032
ARKG 4 Apr 2023 Buy PRME PRIME MEDICINE INC 36,241 0.0215
ARKG 4 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 49,035 0.0215
ARKG 4 Apr 2023 Sell EXAS EXACT SCIENCES CORP 81,009 0.2784
ARKG 4 Apr 2023 Buy BFLY BUTTERFLY NETWORK INC 2,610,056 0.3054
ARKG 3 Apr 2023 Buy SLGC SOMALOGIC INC 231,494 0.0299
ARKG 3 Apr 2023 Buy PRME PRIME MEDICINE INC 38,922 0.0239
ARKG 3 Apr 2023 Buy NRIX NURIX THERAPEUTICS INC 33,370 0.0150
ARKG 3 Apr 2023 Sell ATAI ATAI LIFE SCIENCES NV 119 0.0000
ARKG 31 Mar 2023 Buy SLGC SOMALOGIC INC 121,087 0.0163
ARKG 31 Mar 2023 Buy PRME PRIME MEDICINE INC 35,445 0.0234
ARKG 31 Mar 2023 Buy NRIX NURIX THERAPEUTICS INC 10,302 0.0048
ARKG 31 Mar 2023 Sell INCY INCYTE CORP 26,191 0.1010
ARKG 31 Mar 2023 Sell EXAS EXACT SCIENCES CORP 46,132 0.1681
ARKG 31 Mar 2023 Buy CMPS COMPASS PATHWAYS PLC 44,714 0.0251
ARKG 31 Mar 2023 Sell ATAI ATAI LIFE SCIENCES NV 430 0.0000
ARKG 30 Mar 2023 Buy SLGC SOMALOGIC INC 461,942 0.0593
ARKG 30 Mar 2023 Buy NRIX NURIX THERAPEUTICS INC 109,524 0.0512
ARKG 30 Mar 2023 Sell EXAS EXACT SCIENCES CORP 1,304 0.0047
ARKG 30 Mar 2023 Buy CMPS COMPASS PATHWAYS PLC 69,571 0.0383
ARKG 30 Mar 2023 Sell ATAI ATAI LIFE SCIENCES NV 5,110 0.0004
ARKG 29 Mar 2023 Buy SLGC SOMALOGIC INC 224,229 0.0262
ARKG 29 Mar 2023 Buy NRIX NURIX THERAPEUTICS INC 699 0.0003
ARKG 29 Mar 2023 Sell EXAS EXACT SCIENCES CORP 12,882 0.0474
ARKG 29 Mar 2023 Buy CMPS COMPASS PATHWAYS PLC 14,835 0.0086
ARKG 29 Mar 2023 Sell ATAI ATAI LIFE SCIENCES NV 79,263 0.0062
ARKG 28 Mar 2023 Buy TWST TWIST BIOSCIENCE CORP 32,508 0.0261
ARKG 28 Mar 2023 Buy PRME PRIME MEDICINE INC 288 0.0002
ARKG 28 Mar 2023 Buy NRIX NURIX THERAPEUTICS INC 51,178 0.0240
ARKG 28 Mar 2023 Sell INCY INCYTE CORP 74,457 0.2822
ARKG 28 Mar 2023 Sell ATAI ATAI LIFE SCIENCES NV 1,273,310 0.0892
ARKG 27 Mar 2023 Buy TDOC TELADOC INC 8,031 0.0107
ARKG 27 Mar 2023 Buy PRME PRIME MEDICINE INC 14,700 0.0091
ARKG 27 Mar 2023 Buy NRIX NURIX THERAPEUTICS INC 12,562 0.0060
ARKG 27 Mar 2023 Sell INCY INCYTE CORP 4,070 0.0154
ARKG 23 Mar 2023 Buy TDOC TELADOC INC 37,330 0.0497
ARKG 23 Mar 2023 Sell EXAS EXACT SCIENCES CORP 3,120 0.0112
ARKG 23 Mar 2023 Sell ATAI ATAI LIFE SCIENCES NV 48,358 0.0032
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.